Organon & Co. (NYSE:OGN) Receives Consensus Rating of “Reduce” from Brokerages

Organon & Co. (NYSE:OGN) has received an average rating of “Reduce” from the seven ratings firms that are covering the company, MarketBeat Ratings reports. Five analysts have rated the stock with a sell rating, one has issued a hold rating and one has assigned a strong buy rating to the company. The average 12 month price objective among brokers that have issued ratings on the stock in the last year is $8.50.

Several equities analysts have recently weighed in on the stock. Zacks Research downgraded shares of Organon & Co. from a “hold” rating to a “strong sell” rating in a research note on Thursday, January 29th. Barclays increased their price objective on shares of Organon & Co. from $7.50 to $8.00 and gave the company an “underweight” rating in a report on Tuesday, February 24th. Finally, Wall Street Zen lowered shares of Organon & Co. from a “buy” rating to a “hold” rating in a research note on Saturday, January 31st.

Organon & Co. Price Performance

Shares of NYSE:OGN traded down $0.05 during trading on Friday, reaching $6.01. The stock had a trading volume of 238,874 shares, compared to its average volume of 4,971,729. The company has a debt-to-equity ratio of 11.47, a quick ratio of 1.23 and a current ratio of 1.82. Organon & Co. has a 1-year low of $5.76 and a 1-year high of $14.94. The stock has a market cap of $1.56 billion, a PE ratio of 8.47, a PEG ratio of 0.56 and a beta of 0.60. The business has a fifty day moving average price of $7.53 and a 200-day moving average price of $8.08.

Organon & Co. (NYSE:OGN) last posted its quarterly earnings data on Thursday, February 12th. The company reported $0.63 EPS for the quarter, missing the consensus estimate of $0.73 by ($0.10). Organon & Co. had a net margin of 3.01% and a return on equity of 122.01%. The firm had revenue of $1.51 billion during the quarter, compared to analyst estimates of $1.52 billion. During the same period in the prior year, the company posted $0.90 earnings per share. The firm’s revenue for the quarter was down 5.3% compared to the same quarter last year. On average, equities analysts forecast that Organon & Co. will post 3.68 earnings per share for the current fiscal year.

Organon & Co. Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Thursday, March 12th. Shareholders of record on Monday, February 23rd were paid a dividend of $0.02 per share. The ex-dividend date of this dividend was Monday, February 23rd. This represents a $0.08 dividend on an annualized basis and a yield of 1.3%. Organon & Co.’s payout ratio is 11.27%.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. Foster Dykema Cabot & Partners LLC purchased a new stake in shares of Organon & Co. in the third quarter valued at about $29,000. Farther Finance Advisors LLC grew its stake in shares of Organon & Co. by 87.8% in the 4th quarter. Farther Finance Advisors LLC now owns 4,349 shares of the company’s stock valued at $31,000 after buying an additional 2,033 shares during the period. Rothschild Investment LLC increased its holdings in shares of Organon & Co. by 73.1% during the 3rd quarter. Rothschild Investment LLC now owns 3,899 shares of the company’s stock worth $42,000 after buying an additional 1,646 shares during the last quarter. Eurizon Capital SGR S.p.A. acquired a new stake in shares of Organon & Co. during the 4th quarter worth approximately $44,000. Finally, Kestra Advisory Services LLC purchased a new stake in shares of Organon & Co. during the 4th quarter valued at approximately $47,000. Hedge funds and other institutional investors own 77.43% of the company’s stock.

About Organon & Co.

Organon & Co is a global healthcare company that was established as an independent, publicly traded entity following its spin-off from Merck & Co in June 2021. Headquartered in Jersey City, New Jersey, Organon focuses on delivering therapeutic solutions across women’s health, biosimilars, and established brands. The company’s creation reflected a strategic effort to concentrate on specialty pharmaceuticals and legacy products with proven patient impact.

In women’s health, Organon provides a broad portfolio of products addressing reproductive and gynecological conditions, including fertility treatments, contraception, and hormone replacement therapies.